DrugJul 29, 2026
Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 10 Tablets (10 x 1) unit dose blisters recall — FDA D-0709-2026
Subpotent Drug
Class IIFDA: OngoingMajor Pharmaceuticals
Recall history in this database
Classification mix: Class II: 8, Class III: 2.
DrugJul 29, 2026
Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 10 Tablets (10 x 1) unit dose recall — FDA D-0711-2026
Subpotent Drug
Class IIFDA: OngoingMajor Pharmaceuticals
DrugJul 29, 2026
Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 10 Tablets (10 x 1) unit dose recall — FDA D-0710-2026
Subpotent Drug
Class IIFDA: OngoingMajor Pharmaceuticals
DrugJul 29, 2026
Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 10 Tablets (10 x 1) unit dose blisters recall — FDA D-0707-2026
Subpotent Drug
Class IIFDA: OngoingMajor Pharmaceuticals
DrugJul 29, 2026
Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 10 Tablets (10 x 1) unit dose blisters recall — FDA D-0708-2026
Subpotent Drug
Class IIFDA: OngoingMajor Pharmaceuticals
DrugAug 7, 2019
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS, USP Tablets, 250 mg, 100 count-unit dose carton recall — FDA D-1583-2019
cGMP deviations: Product was exposed above 50% relative humidity levels during packaging operations.
Class IIFDA: TerminatedMAJOR PHARMACEUTICALS
DrugJul 17, 2019
MAJOR PHARMACEUTICALS Losartan Potassium Tablets, USP. 50 mg recall — FDA D-1466-2019
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer
Class IIFDA: TerminatedMAJOR PHARMACEUTICALS
DrugAug 8, 2018
MAJOR PHARMACEUTICALS Doxycycline Hyclate Tablets, USP, 100 mg recall — FDA D-1026-2018
Failed Dissolution Specifications
Class IIFDA: TerminatedMAJOR PHARMACEUTICALS
DrugAug 1, 2018
MAJOR PHARMACEUTICALS Enalapril Maleate Tablets, USP, 5 mg, 100 Tablets (10 x 10) Unit Dose recall — FDA D-0980-2018
Failed Impurities/Degradation Specifications: Sub-recall because this repackaged product was recalled by the manufacturing firm, Wockhardt, due to out-of-specification results for the…
Class IIIFDA: TerminatedMAJOR PHARMACEUTICALS
DrugAug 1, 2018
MAJOR PHARMACEUTICALS Enalapril Maleate Tablets, USP, 2.5 mg, 100 Tablets (10 x 10) Unit recall — FDA D-0979-2018
Failed Impurities/Degradation Specifications: Sub-recall because this repackaged product was recalled by the manufacturing firm, Wockhardt, due to out-of-specification results for the…
Class IIIFDA: TerminatedMAJOR PHARMACEUTICALS
Understanding this recall history
This page summarizes recall records in which the official source identifies Major Pharmaceuticals as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.